Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Merck & Co.

Related MRK
Technical Alert: Merck Higher After Q3 Report
6 Big Pharma Companies Left To Report September Quarterly Figures
Should You Buy Pfizer Now? (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Merck & Co. (NYSE: MRK), but lowered its price target from $49.00 to $47.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Merck & Co. closed on Tuesday at $43.34.

Latest Ratings for MRK

Oct 2016Bank of AmericaUpgradesNeutralBuy
Sep 2016JefferiesMaintainsHold
Sep 2016BarclaysMaintainsOverweight

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!